A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy
- 20 September 2011
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 109 (10), 1495-1502
- https://doi.org/10.1111/j.1464-410x.2011.10555.x
Abstract
Study Type - Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Men with prostate cancer have higher rates of non-cancer mortality and CV morbidity and some of that excess risk has been attributed to the treatment they receive. ADT is an established treatment option for men with locally-advanced and metastatic prostate cancer and, although it has been shown to confer a disease-free survival advantage, it has also been associated with an increased incidence of CV disease and the metabolic syndrome (characterized by a cluster of CV risk factors, including insulin resistance). The benefits of the insulin sensitizer metformin and lifestyle intervention for reducing the incidence of metabolic syndrome have been shown in patients with impaired glucose tolerance. At the time of writing, the present study is the first to use metformin and lifestyle intervention in men with prostate cancer with the aim of reducing the risk of developing ADT-related CV morbidity and the metabolic syndrome. The study shows that lifestyle changes and metformin may indeed reduce the complications of androgen suppression in these men. Although further investigations are needed to establish which of the two interventions may be most beneficial, the favourable effects of a combination of these interventions on patients' quality of life and the potential for improved overall survival are of clinical significanceKeywords
This publication has 37 references indexed in Scilit:
- Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusPublished by Wiley ,2010
- 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyThe Lancet, 2009
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast CancerJournal of Clinical Oncology, 2009
- Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III StudyJournal of Clinical Oncology, 2008
- The rising prevalence of androgen deprivation among older American men since the advent of prostate‐specific antigen testing: a population‐based cohort studyBJU International, 2006
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- The Effect of Androgen Deprivation Therapy on Fasting Serum Lipid and Glucose ParametersJournal of Urology, 2006
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999
- Noncancer Deaths in White Adult Cancer PatientsJNCI Journal of the National Cancer Institute, 1993